본문 바로가기
KERD
논문KCI 등재

Fecal Microbiota Transplantation: An Update on Clinical Practice

Kyeong Ok Kim|Michael Gluck
대한소화기내시경학회 (The Korean Society Of Gastrointestinal Endoscopy)|2019.03|Clinical Endoscopy|제52권 제2호|pp. 137-143|DOI 10.5946/ce.2019.009

2

조회

0

다운로드

4

인용

0

참고문헌

키워드

ColonoscopyFecal microbiota transplantationClostridium diffcile infection
주제분류내과학

초록

Fecal microbiota transplantation (FMT) is an infusion in the colon, or the delivery through the upper gastrointestinal tract, of stoolfrom a healthy donor to a recipient with a disease believed to be related to an unhealthy gut microbiome. FMT has been successfullyused to treat recurrent Clostridium diffcile infection (rCDI). The short-term success of FMT in rCDI has led to investigations of itsapplication to other gastrointestinal disorders and extra-intestinal diseases with presumed gut dysbiosis. Despite the promising resultsof FMT in these conditions, several barriers remain, including determining the characteristics of a healthy microbiome, ensuring thesafety of the recipient with respect to long-term outcomes, adequate monitoring of the recipient of fecal material, achieving high-qualitycontrol, and maintaining reasonable costs. For these reasons, establishing uniform protocols for stool preparation, finding the bestmodes of FMT administration, maintaining large databases of donors and recipients, and assuring that oral ingestion is equivalent tothe more widely accepted colonoscopic infusion are issues that need to be addressed.

Abstract

Fecal microbiota transplantation (FMT) is an infusion in the colon, or the delivery through the upper gastrointestinal tract, of stoolfrom a healthy donor to a recipient with a disease believed to be related to an unhealthy gut microbiome. FMT has been successfullyused to treat recurrent Clostridium diffcile infection (rCDI). The short-term success of FMT in rCDI has led to investigations of itsapplication to other gastrointestinal disorders and extra-intestinal diseases with presumed gut dysbiosis. Despite the promising resultsof FMT in these conditions, several barriers remain, including determining the characteristics of a healthy microbiome, ensuring thesafety of the recipient with respect to long-term outcomes, adequate monitoring of the recipient of fecal material, achieving high-qualitycontrol, and maintaining reasonable costs. For these reasons, establishing uniform protocols for stool preparation, finding the bestmodes of FMT administration, maintaining large databases of donors and recipients, and assuring that oral ingestion is equivalent tothe more widely accepted colonoscopic infusion are issues that need to be addressed.

참고문헌 (57)

  1. Eiseman B, "Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis", Surgery, 44, pp.854~859 (1958)
  2. Chin SM, "Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease : a single-center experience", Clin Gastroenterol Hepatol, 15, pp.597~599 (2017)
  3. Bakken JS, "Treating Clostridium difficile infection with fecal microbiota transplantation", Clin Gastroenterol Hepatol, 9, pp.1044~1049 (2011)
  4. Brandt LJ, "An overview of fecal microbiota transplantation : techniques, indications, and outcomes", Gastrointest Endosc, 78, pp.240~249 (2013)
  5. Gerding DN, "Metronidazole for Clostridium difficile-associated disease:is it okay for Mom?", Clin Infect Dis, 40, pp.1598~1600 (2005)
  6. Wenisch C, "Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea", Clin Infect Dis, 22, pp.813~818 (1996)
  7. Sadowsky MJ, "Faecal microbiota transplantation is promising but not a panacea", Nat Microbiol, 1, pp.16015~ (2016)
  8. Hyun Ho Choi, "Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives", Clinical Endoscopy, 49(3), pp.257~265 (2016), 대한소화기내시경학회
  9. Cammarota G, "Fecal microbiota transplantation for the treatment of Clostridium difficile infection : a systematic review", J Clin Gastroenterol, 48, pp.693~702 (2014)
  10. Kelly CR, "Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection : a randomized trial", Ann Intern Med, 165, pp.609~616 (2016)
  11. van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile", N Engl J Med, 368, pp.407~415 (2013)
  12. Youngster I, "Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors : a randomized, open-label, controlled pilot study", Clin Infect Dis, 58, pp.1515~1522 (2014)
  13. Surawicz CM, "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections", Am J Gastroenterol, 108, pp.478~498 (2013)
  14. Trubiano JA, "Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand", Intern Med J, 46, pp.479~493 (2016)
  15. McDonald LC, "Clinical practice guidelines for Clostridium difficile infection in adults and children : 2017update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA)", Clin Infect Dis, 66, pp.987~994 (2018)
  16. Quraishi MN, "Systematic review with meta-analysis : the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection", Aliment Pharmacol Ther, 46, pp.479~493 (2017)
  17. Moayyedi P, "Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea : a systematic review of randomised controlled trials", Med J Aust, 207, pp.166~172 (2017)
  18. Fischer M, "Fecal microbiota transplant in severe and severe-complicated Clostridium difficile : a promising treatment approach", Gut Microbes, 8, pp.289~302 (2017)
  19. Kelly CR, "Update on fecal microbiota transplantation 2015 : indications, methodologies, mechanisms, and outlook", Gastroenterology, 149, pp.223~237 (2015)
  20. Cammarota G, "European consensus conference on faecal microbiota transplantation in clinical practice", Gut, 66, pp.569~580 (2017)
  21. Vindigni SM, "Fecal microbiota transplantation", Gastroenterol Clin North Am, 46, pp.171~185 (2017)
  22. Zhang SL, "Influence of microbiota on intestinal immune system in ulcerative colitis and its intervention", Front Immunol, 8, pp.1674~ (2017)
  23. Costello SP, "Systematic review with meta-analysis : faecal microbiota transplantation for the induction of remission for active ulcerative colitis", Aliment Pharmacol Ther, 46, pp.213~224 (2017)
  24. Paramsothy S, "Multidonor intensive faecal microbiota transplantation for active ulcerative colitis : a randomised placebo-controlled trial", Lancet, 389, pp.1218~1228 (2017)
  25. Vindigni SM, "The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease : a tripartite pathophysiological circuit with implications for new therapeutic directions", Therap Adv Gastroenterol, 9, pp.606~625 (2016)
  26. Khoruts A, "Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection", Clin Gastroenterol Hepatol, 14, pp.1433~1438 (2016)
  27. Newman KM, "Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease", Gut Microbes, 8, pp.303~309 (2017)
  28. Khanna S, "Management of Clostridium difficile infection in inflammatory bowel disease : expert review from the clinical practice updates committee of the AGA institute", Clin Gastroenterol Hepatol, 15, pp.166~174 (2017)
  29. Johnsen PH, "Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome : a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial", Lancet Gastroenterol Hepatol, 3, pp.17~24 (2018)
  30. Zhou D, "Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota", Sci Rep, 7, pp.1529~ (2017)
  31. Bajaj JS, "Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy : a randomized clinical trial", Hepatology, 66, pp.1727~1738 (2017)
  32. Jayasinghe TN, "The new era of treatment for obesity and metabolic disorders : evidence and expectations for gut microbiome transplantation", Front Cell Infect Microbiol, 6, pp.15~ (2016)
  33. Marco Ruggiero, "Fecal Microbiota Transplantation and the Brain Microbiota in Neurological Diseases", Clinical Endoscopy, 49(6), pp.579~579 (2016), 대한소화기내시경학회
  34. Kelly CR, "Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients", Am J Gastroenterol, 109, pp.1065~1071 (2014)
  35. Kelly BJ, "Clinical practice and infrastructure review of fecal microbiota transplantation for Clostridium difficile infection", Chest, 153, pp.266~277 (2018)
  36. McCune VL, "Faecal transplantation for the treatment of Clostridium difficile infection : a review", Int J Antimicrob Agents, 43, pp.201~206 (2014)
  37. Brandt LJ, "American Journal of Gastroenterology lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection", Am J Gastroenterol, 108, pp.177~185 (2013)
  38. Allegretti JR, "The 5D framework : a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection", Gastrointest Endosc, 87, pp.18~29 (2018)
  39. Kim KO, "Reducing cost and scheduling complexity of fecal microbiota transplantation by using universal donor over patients-directed donors in patients with recurrent Clostrodium difficile infections", Gastroenterology, 154(6 Suppl 1), pp.S191~ (2018)
  40. Edelstein C, "Seeking safe stool : Canada needs a universal donor model", CMAJ, 188, pp.E431~E432 (2016)
  41. Kassam Z, "Fecal microbiota transplantation for Clostridium difficile infection : systematic review and meta-analysis", Am J Gastroenterol, 108, pp.500~508 (2013)
  42. "OpenBiome quality & safety program" (2017)[URL]
  43. Lee CH, "Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection : a randomized clinical trial", JAMA, 315, pp.142~149 (2016)
  44. Kazerouni A, "Optimal screening and donor management in a public stool bank", Microbiome, 3, pp.75~ (2015)
  45. Smith M, "OpenBiome remains open to serve the medical community", Nat Biotechnol, 32, pp.867~ (2014)
  46. Gerding DN, "The epidemiology of Clostridium difficile infection inside and outside health care institutions", Infect Dis Clin North Am, 29, pp.37~50 (2015)
  47. Gough E, "Systematic review of intestinal microbiota transplantation(fecal bacteriotherapy)for recurrent Clostridium difficile infection", Clin Infect Dis, 53, pp.994~1002 (2011)
  48. Youngster I, "Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection", JAMA, 312, pp.1772~1778 (2014)
  49. Fischer M, "Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection : a multicenter study", Am J Gastroenterol, 111, pp.1024~1031 (2016)
  50. Postigo R, "Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection : a review and pooled analysis", Infection, 40, pp.643~648 (2012)
  51. Sofi AA, "Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review", Scand J Gastroenterol, 48, pp.266~273 (2013)
  52. Obi O, "Fecal microbiota transplant for treatment of resistant C. difficile infection using a standardized protocol: a community hospital experience: 2172", Am J Gastroenterol, 109(Suppl 2), pp.S629~ (2014)
  53. Baxter M, "Fatal aspiration pneumonia as a complication of fecal microbiota transplant", Clin Infect Dis, 61, pp.136~137 (2015)
  54. Zipursky JS, "Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection", Clin Infect Dis, 55, pp.1652~1658 (2012)
  55. Kao D, "Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection : a randomized clinical trial", JAMA, 318, pp.1985~1993 (2017)
  56. Allegretti JR, "Fecal microbiota transplantation delivered via oral capsules achieves microbial engraftment similar to traditional delivery modalities: safety, efficacy and engraftment results from a multi-center cluster randomized dose-finding study", Gastroenterology, 150(4 Suppl 1), pp.S540~ (2016)
  57. Allegretti JR, "Classifying fecal microbiota transplantation failure : an observational study examining timing and characteristics of fecal microbiota transplantation failures", Clin Gastroenterol Hepatol, 16, pp.1832~1833 (2018)

관련 논문AI추천

Fecal microbiota transplantation: present and futureIrene Sonu, Ra Ri Cha대한소화기내시경학회 · Clinical Endoscopy2025 · 제58권 제3호Fecal Microbiota Transplantation: Is It Safe?Geom Seog Seo, Seon-Young Park대한소화기내시경학회 · Clinical Endoscopy2021 · 제54권 제2호Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives조영석, Hyun Ho Choi대한소화기내시경학회 · Clinical Endoscopy2016 · 제49권 제3호Next Generation Fecal Microbiota Transplantation나수영, Tae-Geun Gweon대한소화기내시경학회 · Clinical Endoscopy2021 · 제54권 제2호Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile InfectionKim Nayoung, Lee Dong Ho, Park Young Soo, Seol Mijin, Shim Hyun Ik, Shin Cheol Min, Yoon Hyuk거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제1호Recognition and attitudes of Korean physicians toward fecal microbiota transplantation: a survey study조영석, Chang Hwan Choi, on behalf of the Microbiome Research Group of the Korean Society for Neurogastroenterology and Motility, Seung Yong Kim, Sung Kyun Yim, Tae-Geun Gweon, Yoo Jin Lee대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제1호

이 간행물의 다른 논문 (19건)

Usefulness of Probe-Based Confocal Laser Endomicroscopy for Esophageal Squamous Cell Neoplasm이상길pp. 91-92How to Improve the Diagnostic Accuracy of EUS-FNA in Abdominal and Mediastinal Lymphadenopathy?Tae Hyeon Kimpp. 93-94How Can We Differentiate Malignant Biliary Strictures from Clinically Indeterminate Biliary Strictures?조재희, Eui Joo Kimpp. 95-96Do Patients with Pancreatic Hyperenzymemia without Abnormal Imaging Need Additional Endoscopic Ultrasound?Jong Jin Hyun, 최정완pp. 97-99Estimation of Invasion Depth: The First Key to Successful Colorectal ESDTakahisa Matsuda, Bo-In Leepp. 100-106
원문 보기